Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Yanxin Yin, Jia Guo, Fei Teng, Lihua Yu, Yun Jiang, Kun Xie, Ming Jiang & Jianmin Fang. (2019) Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma. Drug Design, Development and Therapy 13, pages 4173-4184.
Read now
Read now
Elmira Safaie Qamsari, Zahra Sharifzadeh, Salman Bagheri, Farhad Riazi-Rad, Vahid Younesi, Mohsen Abolhassani, Sepideh Safaei Ghaderi, Behzad Baradaran, Mohammad Hossein Somi & Mehdi Yousefi. (2017) Isolation and characterization of anti c-met single chain fragment variable (scFv) antibodies. Journal of Immunotoxicology 14:1, pages 23-30.
Read now
Read now
Gabriele Minuti, Armida D'Incecco & Federico Cappuzzo. (2013) Targeted therapy for NSCLC with driver mutations. Expert Opinion on Biological Therapy 13:10, pages 1401-1412.
Read now
Read now
Eric S Kim & Kishan J Pandya. (2013) Advances in personalized therapy for lung cancer. Expert Opinion on Medical Diagnostics 7:5, pages 475-485.
Read now
Read now
Yujiong Wang, Guangcun Deng, Xiaoming Liu & William C Cho. (2013) Monoclonal antibodies in lung cancer. Expert Opinion on Biological Therapy 13:2, pages 209-226.
Read now
Read now
Neil R. Michaud, Jitesh P. Jani, Stephen Hillerman, Konstantinos E. Tsaparikos, Elsa G. Barbacci-Tobin, Elisabeth Knauth, Henry Putz Jr.Mary Campbell, George A. Karam, Boris Chrunyk, David F. Gebhard, Larry L. Green, Jinghai J. Xu, Margaret C. Dunn, Tim M. Coskran, Jean-Martin Lapointe, Bruce D. Cohen, Kevin G. Coleman, Vahe Bedian, Patrick Vincent, Shama Kajiji, Stefan J. Steyn, Gary V. Borzillo & Gerrit Los. (2012) Biochemical and pharmacological characterization of human c-Met neutralizing monoclonal antibody CE-355621. mAbs 4:6, pages 710-723.
Read now
Read now
Christian Klein, Claudio Sustmann, Markus Thomas, Kay Stubenrauch, Rebecca Croasdale, Jürgen Schanzer, Ulrich Brinkmann, Hubert Kettenberger, Jörg T. Regula & Wolfgang Schaefer. (2012) Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. mAbs 4:6, pages 653-663.
Read now
Read now
Articles from other publishers (37)
Annie Ogasawara, James R. Kiefer, Herman Gill, Eugene Chiang, Shravan Sriraman, Gregory Z. Ferl, James Ziai, Sandra Sanabria Bohorquez, Sebastian Guelman, Xiangdan Wang, Jihong Yang, Minh Michael Phan, Van Nguyen, Shan Chung, Christine Yu, Jeff Tinianow, Stijn Jan Hein Waaijer, Alex De Crespigny, Jan Marik, C. Andrew Boswell, Tanja Zabka, Karin Staflin & Simon-Peter Williams. (2022) Preclinical development of ZED8, an 89Zr immuno-PET reagent for monitoring tumor CD8 status in patients undergoing cancer immunotherapy. European Journal of Nuclear Medicine and Molecular Imaging 50:2, pages 287-301.
Crossref
Crossref
Zhengchao Zhang, Dong Li, Heng Yun, Jie Tong, Wei Liu, Keqiang Chai, Tongwei Zeng, Zhenghua Gao & Yongqiang Xie. (2022) Opportunities and challenges of targeting c-Met in the treatment of digestive tumors. Frontiers in Oncology 12.
Crossref
Crossref
Archana Sonkar, Pranesh Kumar, Anurag Gautam, Biswanath Maity & Sudipta Saha. (2022) New Scope of Targeted Therapies in Lung Carcinoma. Mini-Reviews in Medicinal Chemistry 22:4, pages 629-639.
Crossref
Crossref
Joost Neijssen, Rosa M.F. Cardoso, Kristen M. Chevalier, Luus Wiegman, Thomas Valerius, G. Mark Anderson, Sheri L. Moores, Janine Schuurman, Paul W.H.I. Parren, William R. Strohl & Mark L. Chiu. (2021) Discovery of amivantamab (JNJ-61186372), a bispecific antibody targeting EGFR and MET. Journal of Biological Chemistry 296, pages 100641.
Crossref
Crossref
Jie Yang, Qiaoli Wang, Guo‐Kai Feng & Mu‐Sheng Zeng. (2020) Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy. Advanced Therapeutics 3:6, pages 1900210.
Crossref
Crossref
Maike Wittersheim, Simon Schallenberg & Reinhard Büttner. (2019) Nichtkleinzelliges Lungenkarzinom – Pathologie und BiologieNon-small cell lung cancer—pathology and biology. Wiener klinisches Magazin 22:2, pages 60-67.
Crossref
Crossref
Maike Wittersheim, S. Schallenberg & R. Büttner. (2018) Nichtkleinzelliges Lungenkarzinom – Pathologie und BiologieNon-small cell lung cancer—pathology and biology. Der Onkologe 24:12, pages 958-966.
Crossref
Crossref
Paolo M. Comoglio, Livio Trusolino & Carla Boccaccio. (2018) Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. Nature Reviews Cancer 18:6, pages 341-358.
Crossref
Crossref
Hyunkyu Park, Donggeon Kim, Eunmi Kim, Jason Sa, Hee Lee, Suji Yu, Jiwon Oh, Seok-Hyung Kim, Yeup Yoon & Do-Hyun Nam. (2017) Tumor Inhibitory Effect of IRCR201, a Novel Cross-Reactive c-Met Antibody Targeting the PSI Domain. International Journal of Molecular Sciences 18:9, pages 1968.
Crossref
Crossref
Hiu-Fung Yuen, Ka-Kui Chan, Angela Platt-Higgins, El-Habib Dakir, Kyle B. Matchett, Yusuf Ahmed Haggag, Puthen V. Jithesh, Tanwir Habib, Ahmed Faheem, Fennell A. Dean, Richard Morgan, Philip S. Rudland & Mohamed El-Tanani. (2016) Ran GTPase promotes cancer progression via Met receptor-mediated downstream signaling. Oncotarget 7:46, pages 75854-75864.
Crossref
Crossref
Apurva K. Srivastava, Melinda G. Hollingshead, Jennifer Weiner, Tony Navas, Yvonne A. Evrard, Sonny A. Khin, Jiuping Jay Ji, Yiping Zhang, Suzanne Borgel, Thomas D. Pfister, Robert J. Kinders, Donald P. Bottaro, W. Marston Linehan, Joseph E. Tomaszewski, James H. Doroshow & Ralph E. Parchment. (2016) Pharmacodynamic Response of the MET/HGF Receptor to Small-Molecule Tyrosine Kinase Inhibitors Examined with Validated, Fit-for-Clinic Immunoassays. Clinical Cancer Research 22:14, pages 3683-3694.
Crossref
Crossref
Peter Sondermann & David E Szymkowski. (2016) Harnessing Fc receptor biology in the design of therapeutic antibodies. Current Opinion in Immunology 40, pages 78-87.
Crossref
Crossref
Philip T. Cagle, Kirtee Raparia & Bryce P. Portier. 2016. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management. Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
25
36
.
Minghui Dong, Yujie Ren & Xiaodong Gao. (2015) Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure–activity relationships and molecular docking simulations. Bioorganic & Medicinal Chemistry Letters 25:19, pages 4118-4126.
Crossref
Crossref
Elaine M. JagodaSibaprasad BhattacharyyaJoseph KalenLisa RiffleAvrum LeederStephanie HistedMark WilliamsKaren J. WongBiying XuLawrence P. SzajekOsama ElbulukFabiola CecchiKristen RaffenspergerMeghana GollaDonald P. BottaroPeter Choyke. (2015)
Imaging the Met Receptor Tyrosine Kinase (Met) and Assessing Tumor Responses to a Met Tyrosine Kinase Inhibitor in Human Xenograft Mouse Models with a [
99m
Tc] (AH-113018) or CY 5** (AH-112543) Labeled Peptide
. Molecular Imaging 14:9, pages 7290.2015.00023.
Crossref
Crossref
Noëlle Weingertner, Nicolas Meyer, Anne-Claire Voegeli, Dominique Guenot, Stéphane Renaud, Gilbert Massard, Pierre-Emmanuel Falcoz, Anne Olland, Bertrand Mennecier, Marie-Pierre Gaub, Véronique Lindner, Jean-Pierre Ghnassia, Elisabeth Quoix, Marie-Pierre Chenard & Michèle Beau-Faller. (2015) Correlation between MET protein expression and MET gene copy number in a Caucasian cohort of non-small cell lung cancers according to the new IASLC/ATS/ERS classification. Pathology 47:4, pages 320-328.
Crossref
Crossref
B Kim, S Wang, J M Lee, Y Jeong, T Ahn, D-S Son, H W Park, H-s Yoo, Y-J Song, E Lee, Y M Oh, S B Lee, J Choi, J C Murray, Y Zhou, P H Song, K-A Kim & L M Weiner. (2014) Synthetic lethal screening reveals FGFR as one of the combinatorial targets to overcome resistance to Met-targeted therapy. Oncogene 34:9, pages 1083-1093.
Crossref
Crossref
Hans-Ulrich Schildhaus, Anne M. Schultheis, Josef Rüschoff, Elke Binot, Sabine Merkelbach-Bruse, Jana Fassunke, Wolfgang Schulte, Yon-Dschun Ko, Andreas Schlesinger, Marc Bos, Masyar Gardizi, Walburga Engel-Riedel, Michael Brockmann, Monika Serke, Ulrich Gerigk, Khosro Hekmat, Konrad F. Frank, Marcel Reiser, Holger Schulz, Stefan Krüger, Erich Stoelben, Thomas Zander, Jürgen Wolf & Reinhard Buettner. (2015)
MET
Amplification Status in Therapy-Naïve Adeno- and Squamous Cell Carcinomas of the Lung
. Clinical Cancer Research 21:4, pages 907-915.
Crossref
Crossref
Keyu Li, Richard Tavaré, Kirstin A. Zettlitz, Shannon M. Mumenthaler, Parag Mallick, Yu Zhou, James D. Marks & Anna M. Wu. (2014) Anti-MET ImmunoPET for Non–Small Cell Lung Cancer Using Novel Fully Human Antibody Fragments. Molecular Cancer Therapeutics 13:11, pages 2607-2617.
Crossref
Crossref
Hartmut Koeppen, Wei Yu, Jiping Zha, Ajay Pandita, Elicia Penuel, Linda Rangell, Rajiv Raja, Sankar Mohan, Rajesh Patel, Rupal Desai, Ling Fu, An Do, Vaishali Parab, Xiaoling Xia, Tom Januario, Sharianne G. Louie, Ellen Filvaroff, David S. Shames, Ignacio Wistuba, Marina Lipkind, Jenny Huang, Mirella Lazarov, Vanitha Ramakrishnan, Lukas Amler, See-Chun Phan, Premal Patel, Amy Peterson & Robert L. Yauch. (2014) Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clinical Cancer Research 20:17, pages 4488-4498.
Crossref
Crossref
Laura P. Stabile, Mary E. Rothstein, Christopher T. Gubish, Diana E. Cunningham, Nathan Lee & Jill M. Siegfried. (2014) Co-targeting c-Met and COX-2 Leads to Enhanced Inhibition of Lung Tumorigenesis in a Murine Model with Heightened Airway HGF. Journal of Thoracic Oncology 9:9, pages 1285-1293.
Crossref
Crossref
Juergen M. Schanzer, Katharina Wartha, Rebecca Croasdale, Samuel Moser, Klaus-Peter Künkele, Carola Ries, Werner Scheuer, Harald Duerr, Sandra Pompiati, Jan Pollman, Jan Stracke, Wilma Lau, Stefan Ries, Ulrich Brinkmann, Christian Klein & Pablo Umana. (2014) A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. Journal of Biological Chemistry 289:27, pages 18693-18706.
Crossref
Crossref
Emma Shtivelman, Thomas Hensing, George R. Simon, Phillip A. Dennis, Gregory A. Otterson, Raphael Bueno & Ravi Salgia. (2014) Molecular pathways and therapeutic targets in lung cancer. Oncotarget 5:6, pages 1392-1433.
Crossref
Crossref
Jason E. Ekert, Kjell Johnson, Brandy Strake, Jose Pardinas, Stephen Jarantow, Robert Perkinson & David C. Colter. (2014) Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro ? Implication for Drug Development. PLoS ONE 9:3, pages e92248.
Crossref
Crossref
Elaine Mai, Zhong Zheng, Youjun Chen, Jing Peng, Christophe Severin, Ellen Filvaroff, Mally Romero, William Mallet, Surinder Kaur, Thomas Gelzleichter, Ihsan Nijem, Mark Merchant & Judy C. Young. (2014) Nonclinical Evaluation of the Serum Pharmacodynamic Biomarkers HGF and Shed MET following Dosing with the Anti-MET Monovalent Monoclonal Antibody Onartuzumab. Molecular Cancer Therapeutics 13:2, pages 540-552.
Crossref
Crossref
Yasar Albushra Abdul Rahiem Ahmed & Mohamed Ali. (2014) Evaluating the evolving evidence: The challenges of molecular-targeted therapy in management of gastric cancer. Open Journal of Gastroenterology 04:01, pages 6-15.
Crossref
Crossref
R Castoldi, V Ecker, L Wiehle, M Majety, R Busl-Schuller, M Asmussen, A Nopora, U Jucknischke, F Osl, S Kobold, W Scheuer, M Venturi, C Klein, G Niederfellner & C Sustmann. (2013) A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity. Oncogene 32:50, pages 5593-5601.
Crossref
Crossref
Shane A. Olwill, Christian Joffroy, Hendrik Gille, Elisa Vigna, Gabriele Matschiner, Andrea Allersdorfer, Bradley M. Lunde, Jakub Jaworski, James F. Burrows, Cristina Chiriaco, Hans Jürgen Christian, Martin Hülsmeyer, Stefan Trentmann, Kristian Jensen, Andreas M. Hohlbaum & Laurent Audoly. (2013) A Highly Potent and Specific MET Therapeutic Protein Antagonist with Both Ligand-Dependent and Ligand-Independent Activity. Molecular Cancer Therapeutics 12:11, pages 2459-2471.
Crossref
Crossref
Orit Jacobson & Xiaoyuan Chen. (2013) Interrogating Tumor Metabolism and Tumor Microenvironments Using Molecular Positron Emission Tomography Imaging. Theranostic Approaches to Improve Therapeutics. Pharmacological Reviews 65:4, pages 1214-1256.
Crossref
Crossref
W.E.E. Eberhardt, T.C. Gauler & D. Schadendorf. (2013) Neue Entwicklungen in der Behandlung von soliden Tumoren mit zielgerichteten MedikamentenNew developments in treatment of solid tumors with targeted medication. Der Onkologe 19:10, pages 821-834.
Crossref
Crossref
J. Jean Cui, Hong Shen, Michelle Tran-Dubé, Mitchell Nambu, Michele McTigue, Neil Grodsky, Kevin Ryan, Shinji Yamazaki, Shirley Aguirre, Max Parker, Qiuhua Li, Helen Zou & James Christensen. (2013)
Lessons from (
S
)-6-(1-(6-(1-Methyl-1
H
-pyrazol-4-yl)-[1,2,4]triazolo[4,3-
b
]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an Inhibitor of Receptor Tyrosine Kinase c-Met with High Protein Kinase Selectivity but Broad Phosphodiesterase Family Inhibition Leading to Myocardial Degeneration in Rats
. Journal of Medicinal Chemistry 56:17, pages 6651-6665.
Crossref
Crossref
Julin S. Wong, Emma Warbrick, Borek Vojtesek, Jeffrey Hill & David P. Lane. (2013) Anti-c-Met antibodies recognising a temperature sensitive epitope, inhibit cell growth. Oncotarget 4:7, pages 1019-1036.
Crossref
Crossref
Vladimira Koudelakova, Magdalena Kneblova, Radek Trojanec, Jiri Drabek & Marian Hajduch. (2013) Non-small cell lung cancer - genetic predictors. Biomedical Papers 157:2, pages 125-136.
Crossref
Crossref
Barbara Sennino, Toshina Ishiguro-Oonuma, Brian J. Schriver, James G. Christensen & Donald M. McDonald. (2013) Inhibition of c-Met Reduces Lymphatic Metastasis in RIP-Tag2 Transgenic Mice. Cancer Research 73:12, pages 3692-3703.
Crossref
Crossref
Paola Ulivi. (2013) Target therapy in NSCLC patients: Relevant clinical agents and tumour molecular characterisation (Review). Molecular and Clinical Oncology.
Crossref
Crossref
Elaine M. Jagoda, Lixin Lang, Veerendra Bhadrasetty, Stephanie Histed, Mark Williams, Gabriela Kramer-Marek, Esther Mena, Lauren Rosenblum, Jan Marik, Jeff N. Tinianow, Mark Merchant, Lawrence Szajek, Chang Paik, Fabiola Cecchi, Kristen Raffensperger, Joe-Marie Jose-Dizon, Donald P. Bottaro & Peter Choyke. (2012) Immuno-PET of the Hepatocyte Growth Factor Receptor Met Using the 1-Armed Antibody Onartuzumab. Journal of Nuclear Medicine 53:10, pages 1592-1600.
Crossref
Crossref
J. Jean Cui, Michele McTigue, Mitchell Nambu, Michelle Tran-Dubé, Mason Pairish, Hong Shen, Lei Jia, Hengmiao Cheng, Jacqui Hoffman, Phuong Le, Mehran Jalaie, Gilles H. Goetz, Kevin Ryan, Neil Grodsky, Ya-li Deng, Max Parker, Sergei Timofeevski, Brion W. Murray, Shinji Yamazaki, Shirley Aguirre, Qiuhua Li, Helen Zou & James Christensen. (2012)
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1
H
-[1,2,3]triazolo[4,5-
b
]pyrazin-6-yl)-1
H
-pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer
. Journal of Medicinal Chemistry 55:18, pages 8091-8109.
Crossref
Crossref